199 related articles for article (PubMed ID: 19195882)
21. Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Kim I; Song JH; Park CM; Jeong JW; Kim HR; Ha JR; No Z; Hyun YL; Cho YS; Sook Kang N; Jeon DJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):922-6. PubMed ID: 20053559
[TBL] [Abstract][Full Text] [Related]
22. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
23. N-Acylhydrazones as inhibitors of PDE10A.
Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
[TBL] [Abstract][Full Text] [Related]
24. Orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kishikawa K; Obata T; Nakai H; Toda M
Bioorg Med Chem Lett; 2004 Mar; 14(5):1323-7. PubMed ID: 14980691
[TBL] [Abstract][Full Text] [Related]
25. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
26. C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.
Kumar KS; Kiran Kumar S; Yogi Sreenivas B; Gorja DR; Kapavarapu R; Rambabu D; Rama Krishna G; Reddy CM; Basaveswara Rao MV; Parsa KV; Pal M
Bioorg Med Chem; 2012 Apr; 20(7):2199-207. PubMed ID: 22386978
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
Barone FC; Barton ME; White RF; Legos JJ; Kikkawa H; Shimamura M; Kuratani K; Kinoshita M
Pharmacology; 2008; 81(1):11-7. PubMed ID: 17726343
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
[TBL] [Abstract][Full Text] [Related]
30. Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
Gallant M; Aspiotis R; Day S; Dias R; Dubé D; Dubé L; Friesen RW; Girard M; Guay D; Hamel P; Huang Z; Lacombe P; Laliberté S; Lévesque JF; Liu S; Macdonald D; Mancini J; Nicholson DW; Styhler A; Townson K; Waters K; Young RN; Girard Y
Bioorg Med Chem Lett; 2010 Nov; 20(22):6387-93. PubMed ID: 20933411
[TBL] [Abstract][Full Text] [Related]
31. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
[TBL] [Abstract][Full Text] [Related]
32. Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists.
Hudson AR; Higuchi RI; Roach SL; Adams ME; Vassar A; Syka PM; Mais DE; Miner JN; Marschke KB; Zhi L
Bioorg Med Chem Lett; 2011 Mar; 21(6):1697-700. PubMed ID: 21316964
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
Nikpour M; Sadeghian H; Saberi MR; Nick RS; Seyedi SM; Hosseini A; Parsaee H; Bozorg AT
Bioorg Med Chem; 2010 Jan; 18(2):855-62. PubMed ID: 20005117
[TBL] [Abstract][Full Text] [Related]
34. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
Hirose R; Manabe H; Nonaka H; Yanagawa K; Akuta K; Sato S; Ohshima E; Ichimura M
Eur J Pharmacol; 2007 Nov; 573(1-3):93-9. PubMed ID: 17658510
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
36. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
[TBL] [Abstract][Full Text] [Related]
37. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
38. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
[TBL] [Abstract][Full Text] [Related]
39. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
[TBL] [Abstract][Full Text] [Related]
40. Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
Hamaguchi W; Masuda N; Miyamoto S; Kikuchi S; Narazaki F; Shiina Y; Seo R; Amano Y; Mihara T; Moriguchi H; Hattori K
Bioorg Med Chem; 2015 Jul; 23(13):3351-67. PubMed ID: 25960322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]